Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash & Equivalents (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Cash & Equivalents for 16 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 197.55% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.3 million, a 197.55% increase, with the full-year FY2024 number at $430000.0, down 85.29% from a year prior.
  • Cash & Equivalents was $2.3 million for Q3 2025 at NovaBay Pharmaceuticals, down from $5.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $10.5 million in Q1 2021 to a low of $430000.0 in Q4 2024.
  • A 5-year average of $4.8 million and a median of $3.9 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 85.29% in 2024, then surged 611.58% in 2025.
  • NovaBay Pharmaceuticals' Cash & Equivalents stood at $7.5 million in 2021, then dropped by 28.54% to $5.4 million in 2022, then plummeted by 45.47% to $2.9 million in 2023, then crashed by 85.29% to $430000.0 in 2024, then soared by 436.98% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Cash & Equivalents are $2.3 million (Q3 2025), $5.3 million (Q2 2025), and $8.5 million (Q1 2025).